Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
1988-3-10
|
pubmed:abstractText |
Twenty patients with well controlled Type 1 (insulin-dependent) diabetes of at least 10 years duration and 47 control subjects were vaccinated against the hepatitis B virus using the Hevac B vaccine. The vaccine was administered into the deltoid region on three occasions at intervals of 1 month. Thereafter a fourth dose was given to subjects still negative for antibody to hepatitis B surface antigen (HbsAb). The median rise of HbsAb titres was 230 mIU/ml in normal subjects and 50 mIU/ml in diabetic patients (p less than 0.001). Eight patients (40%) failed to reach HbsAb titres above 30 mIU/ml, the level considered to give optimal protection against the infection, whereas only one normal control subject failed to reach this level. Five patients (25%) showed no response despite a fourth dose of the vaccine. There was an increased frequency of HLA-DR7 in low responders and a decreased (less than 1.5) helper/suppressor lymphocyte ratio. Diabetic patients are thus less likely to mount a protective antibody response following vaccination against hepatitis. Since hepatitis B surface antigen is reported to be considerably more common in diabetic patients than control subjects, infection with hepatitis B virus may have a greater risk of chronicity in diabetes.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Surface Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Viral Hepatitis Vaccines
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0012-186X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
30
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
817-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:2962892-Adult,
pubmed-meshheading:2962892-Antibodies, Viral,
pubmed-meshheading:2962892-Antibody Formation,
pubmed-meshheading:2962892-Diabetes Mellitus, Type 1,
pubmed-meshheading:2962892-Female,
pubmed-meshheading:2962892-Hemoglobin A, Glycosylated,
pubmed-meshheading:2962892-Hepatitis B Surface Antigens,
pubmed-meshheading:2962892-Hepatitis B Vaccines,
pubmed-meshheading:2962892-Humans,
pubmed-meshheading:2962892-Male,
pubmed-meshheading:2962892-Reference Values,
pubmed-meshheading:2962892-Viral Hepatitis Vaccines
|
pubmed:year |
1987
|
pubmed:articleTitle |
Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes.
|
pubmed:affiliation |
Endocrinologia I, University of Rome La Sapienza, Italy.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|